COSMOS Pharmaceutical (3349) Q4 2025 earnings summary

Executive summary

• Net sales rose 4.8% year-over-year to ¥1,011,390 million, with operating profit up 28.3% and profit attributable to owners of parent up 26.7%.

• 120 new stores were opened, bringing the total to 1,609, with expansion across all major regions.

• The company maintained its strategy of aggressive store openings despite temporary declines in profitability from self-competition.

Financial highlights

• Operating profit reached ¥40,404 million, up 28.3% year-over-year; ordinary profit was ¥43,160 million, up 25.8%.

• Profit attributable to owners of parent was ¥30,978 million, up 26.7% year-over-year.

• Basic earnings per share increased to ¥390.86 from ¥308.61 (post 2-for-1 stock split basis).

• Gross profit margin improved as gross profit rose to ¥213,281 million from ¥188,305 million.

Outlook and guidance

• Fiscal year ending May 31, 2026 forecast: net sales ¥1,057,000 million (+4.5%), operating profit ¥40,500 million (+0.2%), profit attributable to owners of parent ¥31,000 million (+0.1%).

• Continued focus on low-cost operations and aggressive store expansion, especially in Kanto, Chubu, and Kansai regions.

• Annual dividend forecast for FY2026 is ¥75 per share, up ¥5 from the previous year.